The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Revumenib after transplant shows promise in KMT2A-rearranged and NPM1-mutated AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania discusses a post-hoc analysis from the AUGMENT-101 trial (NCT04065399) evaluating revumenib following allogeneic stem cell transplantation in patients with relapsed/refractory KMT2A-rearranged, NPM1-mutated, and NUP98-rearranged acute myeloid leukemia (AML). He highlights promising relapse-free survival (RFS) outcomes, prolonged treatment exposure, and a manageable safety profile, supporting further investigation of post-transplant menin inhibitor therapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
